Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 260

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

Long-Term Results from an Epiretinal Prosthesis to Restore Sight to the Blind

Open access
Ho, Allen C., Humayun, Mark S., Dorn, Jessy D., da Cruz, Lyndon, Dagnelie, Gislin, Handa, James, Barale, Pierre-Olivier, Sahel, José-Alain, Stanga, Paulo E., Hafezi, Farhad, Safran, Avinoam B., Salzmann, Joel, Santos, Arturo, Birch, David, Spencer, Rand, Cideciyan, Artur V., de Juan, Eugene, Duncan, Jacque L., Eliott, Dean, Fawzi, Amani, Olmos de Koo, Lisa C., Brown, Gary C., Haller, Julia A., Regillo, Carl D., Del Priore, Lucian V., Arditi, Aries, Geruschat, Duane R., Greenberg, Robert J. · 2015 · Ophthalmology

Abstract

PURPOSE: Retinitis pigmentosa (RP) is a group of inherited retinal degenerations leading to blindness due to photoreceptor loss. Retinitis pigmentosa is a rare disease, affecting only approximately 100 000 people in the United States. There is no cure and no approved medical therapy to slow or reverse RP. The purpose of this clinical trial was to evaluate the safety, reliability, and benefit of the Argus II Retinal Prosthesis System (Second Sight Medical Products, Inc, Sylmar, CA) in restoring some visual function to subjects completely blind from RP. We report clinical trial results at 1 and 3 years after implantation. DESIGN: The study is a multicenter, single-arm, prospective clinical trial. PARTICIPANTS: There were 30 subjects in 10 centers in the United States and Europe. Subjects served as their own controls, that is, implanted eye versus fellow eye, and system on versus system off (native residual vision). METHODS: The Argus II System was implanted on and in a single eye (typically the worse-seeing eye) of blind subjects. Subjects wore glasses mounted with a small camera and a video processor that converted images into stimulation patterns sent to the electrode array on the retina. MAIN OUTCOME MEASURES: The primary outcome measures were safety (the number, seriousness, and relatedness of adverse events) and visual function, as measured by 3 computer-based, objective tests. RESULTS: A total of 29 of 30 subjects had functioning Argus II Systems implants 3 years after implantation. Eleven subjects experienced a total of 23 serious device- or surgery-related adverse events. All were treated with standard ophthalmic care. As a group, subjects performed significantly better with the system on than off on all visual function tests and functional vision assessments. CONCLUSIONS: The 3-year results of the Argus II trial support the long-term safety profile and benefit of the Argus II System for patients blind from RP. Earlier results from this trial were used to gain approval of the Argus II by the Food and Drug Administration and a CE mark in Europe. The Argus II System is the first and only retinal implant to have both approvals.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ophtha.2015.04.032

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Cited by

See all 260

Metadata

Authors
Ho, A. C., Humayun, M. S., Dorn, J. D., da Cruz, L., Dagnelie, G., Handa, J., Barale, P.-O., Sahel, J.-A., Stanga, P. E., Hafezi, F., Safran, A. B., Salzmann, J., Santos, A., Birch, D., Spencer, R., Cideciyan, A. V., de Juan, E., Duncan, J. L., Eliott, D., Fawzi, A., Olmos de Koo, L. C., Brown, G. C., Haller, J. A., Regillo, C. D., Del Priore, L. V., Arditi, A., Geruschat, D. R., & Greenberg, R. J.
Venue
Ophthalmology
Publisher
Elsevier BV
Published
2015-08
Volume
122
Issue
8
Pages
1547-1554
ISSN
0161-6420 (ISSN-L)
OpenAlex
W1912107527
Cited by
260
References
18
FWCI
15.53
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-Term Results from an Epiretinal Prosthesis to Restore Sight to the Blind. https://app.cochat.ai/papers/10.1016/j.ophtha.2015.04.032
The paper
Ho, A. C., Humayun, M. S., Dorn, J. D., da Cruz, L., Dagnelie, G., Handa, J., Barale, P.-O., Sahel, J.-A., Stanga, P. E., Hafezi, F., Safran, A. B., Salzmann, J., Santos, A., Birch, D., Spencer, R., Cideciyan, A. V., de Juan, E., Duncan, J. L., Eliott, D., . . . Greenberg, R. J. (2015). Long-Term Results from an Epiretinal Prosthesis to Restore Sight to the Blind. Ophthalmology. https://doi.org/10.1016/j.ophtha.2015.04.032

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.